Shanghai, China, May 7, 2019 — MilliporeSigma, a leading science and technology company, today announced that MDL, a team from Beijing University, has won the company’s first Retrosynthetic Reaction Prediction Contest.
Contestants were required to design a model for retrosynthetic analysis based on given chemical reactions data, and then predict the materials used according to the target reagents and product. Selected by a panel of judges including MilliporeSigma scientists, MDL won an RMB 22,000 cash prize for designing a hybrid modelling strategy for retrosynthetic analysis using a combination of artificial intelligence algorithms and research.
“As a leader in retrosynthesis, MilliporeSigma is dedicated to advancing science and technology in this space, and we look forward to learning from and acknowledging research from curious scientists,” said Steve Vermant, managing director, head of Research Solutions Commercial, Life Science at MilliporeSigma in China. “This contest provides a thought-provoking platform for students, researchers and practitioners to share ideas and innovation, and helps accelerate applications of new technology while also developing new talent.”
Other winners included:
Retrosynthetic analysis plays a critical role in the development of new drugs, and its application has broad prospects especially in accelerating speed of drug research and development improving efficiency and reducing costs.
The contest, open to anyone in China, included a training camp, online knowledge sharing, as well as workshops, lab tours and mentorship for participants. The contest attracted 1,150 contestants, many of whom were students majoring in engineering, computer science, chemistry and medicine, from universities including Beijing University, Tsinghua University and Fudan University. Other contestants were researchers and practitioners with medical and life science backgrounds from institutions and corporations including Shanghai Institute of Materia Medica, Chinese Academy of Sciences, JD.com and PingAn Technology.
Participants worked in teams to generate new ideas, learn from one another and solve problems with support from MilliporeSigma scientists. MilliporeSigma launched the retrosynthetic analysis contest to promote exploration of artificial intelligence, machine learning in drug design and computer-aided drug design.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany generated sales of €16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.